Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.69 |
| ▸ | PGR | P06401 | 6/20 | 0.69 |
| ▸ | USP2 | O75604 | 5/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | MLNR | O43193 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobetasone Butyrate SCHEMBL11750078 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL36599 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL29410388 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL29572705 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL11124627 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| Clobetasone Butyrate SCHEMBL14339619 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL732359 | 0.96 | LMNA (0.92) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL568167 | 0.94 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL28099304 | 0.94 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 | |
| SCHEMBL11748908 | 0.93 | LMNA (0.87) | LMNAMAPTSMN1; SMN2NPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1993 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4301343-B1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4178579-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240216286-A1 | NANOSPHERE AND USE THEREOF | CHANG GUNG UNIVERSITY (TW) | 2024-07-04 | — | — | US | claimed |
| US-20240156839-A1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS, INC. | 2024-05-16 | — | — | US | claimed |
| EP-3728203-B1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX INC (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4301343-A1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC Biopharmaceuticals, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230241060-A1 | GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2023-08-03 | — | — | US | claimed |
| WO-2012068454-A2 | NRF2 DEFICIENCY INFLUENCES SUSCEPTIBILITY TO STEROID RESISTANCE VIA HDAC2 REDUCTION | UNIVERSITY OF ROCHESTER (US) | 2012-05-24 | — | — | WO | claimed |
| WO-2011064661-A1 | SMALL PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | PROTEOLOGICS, LTD. (IL) | 2011-06-03 | — | — | WO | claimed |
| WO-2011064657-A2 | QUINAZOLIN-4(3A)-ONE DERIVATIVES AND METHODS OF USE THEREOF | PROTEOLOGICS, LTD. (IL) | 2011-06-03 | — | — | WO | claimed |
| US-20110130374-A1 | Small Pyrimidine Derivatives and Methods of Use Thereof | BIOSEARCH(2007) LTD. (IL) | 2011-06-02 | — | — | US | claimed |
| US-20110129463-A1 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof | PROTEOLOGICS, LTD. (IL) | 2011-06-02 | — | — | US | claimed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| EP-1890679-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2008-02-27 | — | — | EP | claimed |
| WO-2007012977-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | FOAMIX LTD (US) | 2007-02-01 | — | — | WO | claimed |
| US-20060193789-A1 | Surfacant, film forming agent, water, gas propellant; plant and animal extracts and oils; may include malathion | FOAMIX LTD. (IL) | 2006-08-31 | — | — | US | claimed |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | FOAMIX LTD. | 2006-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | LMNA 266/4885MAPT 4587/4885SMN1; SMN2 3037/4885 |
| US-20110129463-A1 | Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof | USP3, CUL3, UBQLN1 | LMNA 2099/4885MAPT 1775/4885SMN1; SMN2 3546/4885 |
| US-20110130374-A1 | Small Pyrimidine Derivatives and Methods of Use Thereof | TYMS, UPP1, DPYD | LMNA 3820/4885MAPT 3063/4885SMN1; SMN2 4590/4885 |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | KIT, GK, HSD17B7 | LMNA 1235/4885MAPT 3575/4885SMN1; SMN2 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.